Anna J Podolanczuk Selected Research

Atherosclerosis

1/2022	Associations of Monocyte Count and Other Immune Cell Types with Interstitial Lung Abnormalities.
11/2021	Associations of D-Dimer with Computed Tomographic Lung Abnormalities, Serum Biomarkers of Lung Injury, and Forced Vital Capacity: MESA Lung Study.
1/2021	Associations of ω-3 Fatty Acids With Interstitial Lung Disease and Lung Imaging Abnormalities Among Adults.
1/2020	Associations of Serum Adipokines With Subclinical Interstitial Lung Disease Among Community-Dwelling Adults: The Multi-Ethnic Study of Atherosclerosis (MESA).
12/2019	Overlap of Genetic Risk between Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis.
1/2018	Collagen biomarkers and subclinical interstitial lung disease: The Multi-Ethnic Study of Atherosclerosis.
1/2018	Serum 25-Hydroxyvitamin D Concentrations Are Associated with Computed Tomography Markers of Subclinical Interstitial Lung Disease among Community-Dwelling Adults in the Multi-Ethnic Study of Atherosclerosis (MESA).
1/2017	Cholesterol, lipoproteins and subclinical interstitial lung disease: the MESA study.
11/2016	High attenuation areas on chest computed tomography in community-dwelling adults: the MESA study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anna J Podolanczuk Research Topics

Disease

11	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2023 - 01/2017
9	Atherosclerosis 01/2022 - 11/2016
5	Idiopathic Pulmonary Fibrosis 12/2023 - 11/2017
3	Pulmonary Fibrosis (Fibrosing Alveolitis) 04/2024 - 12/2023
2	Disease Progression 01/2023 - 01/2022
2	Chronic Obstructive Pulmonary Disease (COPD) 01/2022 - 12/2019
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2018 - 01/2017
1	Lung Diseases (Lung Disease) 02/2024
1	Fatigue 01/2023
1	COVID-19 10/2022
1	Gastroesophageal Reflux (GERD) 06/2022
1	Pulmonary Hypertension 06/2022
1	Cough 01/2022
1	Cicatrix (Scar) 11/2021
1	Lung Injury 11/2021
1	Fibrosis (Cirrhosis) 01/2018
1	Frailty 10/2017
1	Inflammation (Inflammations) 11/2016

Drug/Important Bio-Agent (IBA)

9	Biomarkers (Surrogate Marker)IBA 12/2023 - 11/2016
2	nintedanibIBA 02/2024 - 01/2023
2	Matrix Metalloproteinase 7 (Matrilysin)IBA 11/2017 - 11/2016
1	SteroidsIBA 01/2023
1	Tyrosine Kinase InhibitorsIBA 01/2023
1	Oxygen (Dioxygen)IBA 01/2023
1	casirivimab and imdevimab drug combinationIBA 10/2022
1	Type I DNA Topoisomerases (Topoisomerase I)IBA 06/2022
1	Thrombin FDA Link 11/2021
1	FibrinIBA 11/2021
1	Pulmonary Surfactant-Associated Protein A (Surfactant Protein A)IBA 11/2021
1	fibrin fragment D (D-dimer)IBA 11/2021
1	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/2021
1	Acetylcysteine (Siran)FDA LinkGeneric 01/2021
1	Docosahexaenoic AcidsIBA 01/2021
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2021
1	ResistinIBA 01/2020
1	LeptinIBA 01/2020
1	AdipokinesIBA 01/2020
1	AdiponectinIBA 01/2020
1	Angiotensin Receptor AntagonistsIBA 11/2019
1	CollagenIBA 01/2018
1	Collagen Type I (Type I Collagen)IBA 01/2018
1	Collagen Type III (Type III Collagen)IBA 01/2018
1	procollagen Type III-N-terminal peptide (PIIP)IBA 01/2018
1	hydroxide ionIBA 01/2018
1	25-hydroxyvitamin DIBA 01/2018
1	Clostridium perfringens epsilon-toxinIBA 10/2017
1	CholesterolIBA 01/2017
1	Lipoproteins (Lipoprotein)IBA 01/2017
1	Interleukin-6 (Interleukin 6)IBA 11/2016

Therapy/Procedure

2	Therapeutics 12/2023 - 01/2023
2	Lung Transplantation 01/2023 - 01/2022
1	Precision Medicine 04/2024
1	Palliative Care (Palliative Therapy) 01/2023